Clinical Trial Update: Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial update assessing intravesical TARA-002 versus investigator's choice intravesical chemotherapy for BCG-naïve high-grade non-muscle invasive bladder…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Carcinoma in Situ of the Bladder
• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• TARA-002

Snippet

Sponsor: Protara Therapeutics | Conditions: Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma | Phase 3 | Status: NOT_YET_RECRUITING